The FDA has approved a new oral antibiotic to treat uncomplicated urinary tract infections. Orylnvah is a broad-spectrum oral penem antibiotic for women who have limited or no alternative ...

The FDA has approved Genentech’s inavolisib (Itovebi) in combination with the CDK4/6 inhibitor palbociclib and the oestrogen-receptor antagonist fulvestrant for endocrine-resistant, PIK3CA ...

The U.S. FDA recently approved FluMist as a self or caregiver-administered nasal spray flu vaccine to prevent Influenza disease. The nasal spray prevents the flu from Influenza virus subtypes A ...

The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections (uUTIs). Orlynvah (sulopenem etzadroxil and probenecid) is a broad-spectrum ...

WASHINGTON — Jazz Pharmaceuticals lost its bid to overturn the approval of another company’s rival sleep drug when a D.C. federal judge ruled that the FDA did not violate the Orphan Drug Act when ...

The Food and Drug Administration approved a drug produced by AbbVie for the treatment of late stage Parkinsons disease the company announced Thursday. The regulator approved Vyalev, also known as ...

Oct. 14, 2024 – A new breast cancer drug has received quick federal approval after a clinical trial showed it could more than double the time before a common type of breast cancer recurrence ...

Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...

The US Food and Drug Administration (FDA) has approved AbbVie's VYALEV (foscarbidopa and foslevodopa) to treat motor fluctuations in adults with advanced Parkinson's disease (PD). The chronic ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pfizer has earned a nod from the U.S. regulator for another of its products in the indication. On Friday, the FDA signed ...

Common side effects include decreased neutrophils, increased glucose, fatigue, and stomatitis, affecting over 20% of patients. The Food and Drug Administration (FDA) has approved Itovebi (inavolisib) ...

Optune Lua is FDA approved for use with immunotherapy or docetaxel in metastatic stage IV NSCLC post-platinum treatment. The device uses tumor treating fields to disrupt cancer cell division ...